Unituxin (Dinutuximab Vials) 17.5mg/5ml

Unituxin (dinutuximab) is a monoclonal antibody used in pediatric oncology. This 17.5mg/5ml vial supports targeted therapy protocols. Store between 2-8°C to maintain stability. Consult healthcare provider for individualized treatment plans.

Strength

17.5mg/5ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

United Therapeutics Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Dinutuximab is primarily used in combination with other medications to treat high-risk neuroblastoma in pediatric patients who have achieved at least a partial response to prior first-line therapy. This targeted therapy works by binding to specific antigens on neuroblastoma cells, helping the immune system recognize and attack cancerous cells. It is typically administered in clinical settings as part of a comprehensive treatment regimen.

Side Effects

Patients receiving dinutuximab may experience infusion-related reactions, including fever, low blood pressure, and pain. Some individuals report fatigue, nausea, or skin rashes during treatment. These effects are generally monitored closely by healthcare professionals to ensure patient safety and comfort throughout therapy.

Precautions & Warnings

Dinutuximab requires careful handling and administration under medical supervision. Patients should be monitored for signs of infusion reactions or allergic responses. Keep the vial refrigerated between 2-8°C and protect from light. Discard any unused portion as directed by healthcare guidelines to maintain sterility and efficacy.

Avoid Interactions

Dinutuximab may interact with other medications that suppress the immune system, potentially increasing infection risk. Concurrent use of live vaccines should be avoided during treatment. Patients should inform their healthcare provider about all prescription, over-the-counter, and herbal products being used to minimize potential interaction risks.

Frequently Asked Questions

Unituxin (dinutuximab) is used to treat high-risk neuroblastoma in children who have responded partially to initial therapy.

It is given as an intravenous infusion in a clinical setting under medical supervision.

Common effects include fever, pain, fatigue, and infusion-related reactions.

No, it must be refrigerated between 2-8°C and protected from light.

No, it is a monoclonal antibody used in targeted therapy for neuroblastoma.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.